Accordingly, pharmacological inhibition of these pathways decreased PD-L1 expression in the corresponding in vitro and in vivo models of cancer [173,174,175] and conferred sensitivity to PD-1/PD-L1 axis blockade [171]. Here, PDCD1 is linked to cancer.